TGFB1 and osteoarthritis: Invossa TissueGene C, an allogeneic cell and gene therapy based on TGF-β1 transfected polydactyly chondrocytes, is currently commercially available in South Korea and undergoing phase III clinical trials in the USA for severe osteoarthritis indications.